Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companies unveiled positive data from a study in chronic spontaneous urticaria (CSU) and a ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Dupixent is available in China in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous injection ...

Dupixent is available in China in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous injection ...

Dupixent, an interleukin-4 receptor alpha antagonist ... The recommended dosage for patients aged 12 years and older with CRSwNP is 300mg every other week by subcutaneous injection.

Treatment with dupilumab led to significant improvements in remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...